Up Front MattersBrief Reviews

Bicarbonate Balance and Prescription in ESRD

Matthew K. Abramowitz
JASN March 2017, 28 (3) 726-734; DOI: https://doi.org/10.1681/ASN.2016070780

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

The optimal approach to managing acid-base balance is less well defined for patients receiving hemodialysis than for those receiving peritoneal dialysis. Interventional studies in hemodialysis have been limited and inconsistent in their findings, whereas more compelling data are available from interventional studies in peritoneal dialysis. Both high and low serum bicarbonate levels associate with an increased risk of mortality in patients receiving hemodialysis, but high values are a marker for poor nutrition and comorbidity and are often highly variable from month to month. Measurement of pH would likely provide useful additional data. Concern has arisen regarding high-bicarbonate dialysate and dialysis-induced alkalemia, but whether these truly cause harm remains to be determined. The available evidence is insufficient for determining the optimal target for therapy at this time.

Metabolic acidosis was one of the earliest recognized complications of uremia.1 Several of the initial reports of dialysis therapy demonstrated its correction by diffusion of bicarbonate from dialysis fluid to uremic blood.2–4 In the decades since, significant technologic improvements have occurred, but the basic concept for acid-base regulation remains the same. Thus it is somewhat surprising that controversy persists about the proper prescription of bicarbonate dialysis and even the appropriate target for therapy.

This was aptly illustrated in the last several years. In 2012 a large dialysis provider faced a spate of lawsuits stemming from a memo addressing acid-base status and the use of its acetate-containing dialysates.5,6 The memo recommended changes to dialysis prescriptions on the basis of an association of high serum bicarbonate with mortality. For many nephrologists in the United States, this case created confusion about bicarbonate dialysis and added medico-legal significance to the hemodialysis prescription. It is useful to consider why such uncertainty still exists.

Rationale for Treatment of Metabolic Acidosis in ESRD

Patients with ESRD appear to be in net acid-base balance.7 Thrice-weekly hemodialysis creates a cycle of rapid correction of acidosis that causes transient alkalemia of varying degree, followed by acid retention during the ensuing 44–68 hours. Patients treated with peritoneal dialysis experience nearly continuous buffer repletion. In neither group does net acid retention occur.7,8 However, sequelae of their residual acidosis were identified, including altered protein, muscle, and bone metabolism.9–12 Correction of metabolic acidosis in patients with ESRD improved insulin sensitivity and reduced whole-body and skeletal muscle protein breakdown.13–17 It also enhanced parathyroid gland sensitivity to calcium and improved bone turnover in both high- and low-turnover states.18,19 However, the findings of interventional studies in patients receiving hemodialysis were somewhat inconsistent, and were limited by small sample sizes and lack of a control group in some.20–25

The most compelling data came from two trials in patients treated with continuous ambulatory peritoneal dialysis. In a randomized, double-blind, placebo-controlled trial of 60 patients, those assigned to oral sodium bicarbonate had improved nutritional status and experienced fewer hospitalizations after 1 year.26 Correction of acidosis in another single-blind randomized trial of 200 patients receiving peritoneal dialysis increased lean body mass and reduced hospitalizations.27 The latter intervention targeted a serum bicarbonate of 30 mEq/L using dialysate with 40 mmol/L lactate (compared with 35 mmol/L in the control group), calcium carbonate, plus oral sodium bicarbonate as needed. Notably, the intervention groups in both studies achieved mean serum bicarbonate levels of approximately 28 mEq/L or higher, which not only was well tolerated but which resulted in improved outcomes. Peritoneal dialysis solutions containing 40 mmol/L lactate are now standard.

Serum Bicarbonate Levels in Patients Receiving Hemodialysis

As these findings were reported, predialysis serum bicarbonate levels among patients receiving hemodialysis increased. Among 12,099 patients receiving hemodialysis in the United States in 1987–88, the mean serum bicarbonate was 19.2 mEq/L28; in contrast, the mean serum bicarbonate was 21.4 mEq/L in 4515 United States patients receiving hemodialysis in the Dialysis Outcomes and Practice Patterns Study (DOPPS) from 1996–2001,29 and was 21.9 mEq/L among 56,385 patients who received hemodialysis from 2001–03.30 More striking is that the percentage of patients with serum bicarbonate <21 mEq/L declined from 75% in the 1987–88 cohort to 35% in the 2001–03 cohort.28,30

Several factors explain this trend. The switch from acetate to bicarbonate as the main source of dialysate buffer replacement improved correction of acidosis.31–33 The use of higher blood flows and high-efficiency membranes would be expected to increase bicarbonate delivery, but may not have had an effect.34 Nephrologists may have targeted low serum bicarbonate values more aggressively, especially after an initial observational study that associated levels of 20–22.5 mEq/L with the lowest risk of death.28 In 2000 the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) recommended maintaining predialysis serum bicarbonate at ≥22 mEq/L,35 which would have further spurred treatment of low bicarbonate levels. Secular trends also could have played a role, such as the increasing age of patients initiating dialysis in the United States. Older Americans have higher serum bicarbonate levels than younger Americans, partly due to lower animal protein intake and hence lower dietary acid load.36 Older age is associated with higher serum bicarbonate in patients with ESRD as well.37–39 Therefore, it is conceivable that the increasing age of incident dialysis patients has contributed to increasing serum bicarbonate levels.

Despite these changes, a substantial proportion of patients do not meet the KDOQI target. From 2001 to 2006 at one large dialysis provider, 40% of 110,951 patients receiving hemodialysis had a time-averaged predialysis serum bicarbonate <22 mEq/L.39 Only 5% had serum bicarbonate ≥27 mEq/L.39 Nevertheless, changes in practice due to recent concerns about high serum and dialysate bicarbonate levels could increase the proportion of patients with low predialysis serum bicarbonate levels.

Pre- and Postdialysis Bicarbonate Levels and Mortality in Patients Receiving Hemodialysis

Both high and low serum bicarbonate levels have been associated with an increased risk of mortality in observational studies of patients receiving hemodialysis (total carbon dioxide [CO2], generally 1–1.5 mEq/L higher than the serum bicarbonate concentration, is actually what is measured in all epidemiologic studies unless otherwise noted).28–30 The association of low bicarbonate with mortality is magnified after adjustment for markers of nutrition, comorbidity, and inflammation, whereas that of high bicarbonate is markedly attenuated.30,39 This suggests that high predialysis serum bicarbonate is a marker for patients with poor nutrition, ongoing inflammation, and a high burden of comorbidity. Indeed, serum bicarbonate correlates inversely with normalized protein catabolic rate, serum albumin, and serum phosphate in patients with ESRD.30,37,38 Put simply, sicker patients eat less protein, resulting in less acid generation. Thus the association is unlikely to represent a causal relationship.

Some have expressed concern about the use of high dialysate bicarbonate or total alkali (the sum of bicarbonate plus an organic anion, such as acetate or citrate) concentrations on the basis of these findings. In general, patients being dialyzed against a high-bicarbonate bath do have higher predialysis bicarbonate levels.24,25,39 However, there are clearly other important determinants of predialysis serum bicarbonate (Table 1). The United States and Japan were at opposite ends of the spectrum in terms of dialysate bicarbonate levels from 1996 to 2001 (highest and lowest, respectively) but had the same mean serum bicarbonate—21.4 mEq/L, or the lowest of seven nations surveyed.29 A number of factors account for this finding. Whereas lower blood flows in Japan would reduce net bicarbonate gain, longer treatment times and smaller average body size compared with the average United States patient receiving hemodialysis would increase net bicarbonate transfer into a smaller bicarbonate space.40,41 Daily acid production is likely lower for the average Japanese patient due to the lower dietary acid load of the Japanese diet, further reducing the amount of buffer repletion needed to achieve a given bicarbonate level.

View this table:
Table 1.

Determinants of pre- and posthemodialysis serum bicarbonate

Differences in endogenous acid production, largely determined by dietary intake, account for some of the interindividual variability in serum bicarbonate levels.30,34,37,38 Interdialytic weight gain lowers the bicarbonate level by expanding the bicarbonate space.34,42–44 Serum bicarbonate is approximately 1 mEq/L lower after the long interdialytic interval than the short interval.29,45,46 Medication use is important as well; sevelamer hydrochloride reduces serum bicarbonate, whereas phosphate binders containing alkali precursors do the opposite.47–51

Net alkali gain during dialysis and its volume of distribution determine the postdialysis serum bicarbonate (Table 1). This sets the starting point for the linear decline that most patients experience between treatments.45 The change in serum bicarbonate during hemodialysis correlates with the dialysate–serum bicarbonate gradient (Figure 1A) and relates inversely to the predialysis level (Figure 1B), so patients with the highest levels at the initiation of treatment experience modest increases (Figure 2).52–54 In a stable chronic hemodialysis patient, net alkali gain during dialysis should equal the total net acid production in the interdialytic period. When measured, this quantity has been quite variable among patients.53,55 In some individuals, the change in bicarbonate may be blunted due to organic anion generation.34 Because this variability has not been quantified, its significance remains unclear. Dialysis dose and ultrafiltration rate, by affecting bicarbonate delivery, are also important (the latter reduces net bicarbonate gain). Finally, in a minority of patients the bicarbonate level does not decrease appreciably between treatments.45

Figure 1.
Figure 1.

Change in serum bicarbonate during hemodialysis correlates directly with dialysate-serum gradient and inversely with predialysis concentration. Intradialytic change in serum bicarbonate versus (A) dialysate–serum bicarbonate gradient and (B) predialysis serum bicarbonate level among chronic hemodialysis patients dialyzed against 35 mEq/L (15 patients, Uribarri et al.); 36 mEq/L (70 patients, Sepandj et al.); and 25, 30, or 35 mEq/L (53 patients, Noh et al.) bicarbonate dialysate. Data from Uribarri et al.,53 Sepandj et al.,54 and Noh et al.52 Intradialytic increase in serum bicarbonate per 1 mEq/L higher predialysis serum bicarbonate = −0.55 mEq/L (95% confidence interval [95% CI], −0.68 to −0.43); for individual studies, the slope was −0.54 mEq/L (95% CI, −0.81 to −0.28) for Uribarri et al., −0.55 mEq/L (95% CI, −0.69 to −0.41) for Sepandj et al., and −0.43 mEq/L (95% CI, −0.66 to −0.20) for Noh et al. P for interaction by study = 0.63.

Figure 2.
Figure 2.

Theoretical bicarbonate profiles in hemodialysis. Profiles of serum bicarbonate changes for patients receiving hemodialysis with midweek predialysis serum bicarbonate of 20 and 28 mEq/L, respectively. Profiles assume dialysate bicarbonate of 35 mEq/L and intradialytic increases on the basis of point estimates derived from linear regression of data from Uribarri et al.53 and Sepandj et al.54 (predicted intradialytic increase 7.7 mEq/L [95% confidence interval, 7.2 to 8.3] and 2.8 mEq/L [95% confidence interval, 2.1 to 3.5] for predialysis serum bicarbonate of 20 and 28 mEq/L, respectively).

A recent study of 15,132 Japanese patients receiving hemodialysis provided important new data by examining blood gas measurements at the beginning and end of hemodialysis.56 Although the aforementioned differences between the United States and Japan may limit generalizability, these data provide insights into hemodialysis-induced acid-base changes in a large cohort of patients. Surprisingly, neither high pH nor serum bicarbonate measured at the end of dialysis associated with mortality. Rather, patients in the highest pH quartile before dialysis (pH ≥7.40) had the greatest mortality after multivariable adjustment. As expected, predialysis bicarbonate was higher for these patients than the rest of the cohort, but the partial pressure of carbon dioxide (pCO2) was lower, suggesting a degree of respiratory alkalosis. Indeed, in a small cohort of Italian patients receiving hemodialysis, predialysis pH ≥7.40 most often indicated respiratory alkalosis, sometimes with a concomitant metabolic disorder.46 Predialysis serum bicarbonate was also a poor predictor of predialysis pH.46 These data show that the association of high predialysis serum bicarbonate with mortality is not mediated by alkalemia due to excessive alkali delivery.

Rather, they support the hypothesis that underlying comorbidity explains the mortality risk observed with predialysis alkalemia and high serum bicarbonate. The mean pCO2 rose during dialysis in the group with predialysis alkalemia.56 This suggests they are sicker and less able to appropriately increase minute ventilation in the face of increased CO2 generation with bicarbonate dialysis.57 Higher pCO2 levels could explain the nonsignificant trend toward increased mortality among patients with the lowest pH (<7.40) after dialysis. Indeed, higher normalized protein catabolic rate, a marker for better nutritional status, was unexpectedly associated with a greater likelihood of postdialysis alkalemia. This is surprising because it also associated, as expected, with lower serum bicarbonate postdialysis. The association with postdialysis pH can then only be explained by changes in CO2 excretion during dialysis. The implication is that patients with better nutritional status are more likely to manifest an appropriate respiratory response during hemodialysis.

Finally, the Japanese data do not support the hypothesis that patients with high predialysis serum bicarbonate are most likely to experience severe alkalemia during a hemodialysis treatment. The difference in pH between the highest and lowest bicarbonate quartiles was 0.10 pH units before dialysis but only 0.03 pH units after dialysis.56 That the pH difference shrank during hemodialysis suggests that patients with high predialysis serum bicarbonate experience the least fluctuation in pH, consistent with the data on intradialytic change in serum bicarbonate described above. Therefore, the totality of available data indicates that high predialysis bicarbonate levels are not a useful biomarker for guiding changes in the bicarbonate dialysis prescription.

Prescription of Bicarbonate Hemodialysis

There are still other reasons for concern over the use of high-bicarbonate dialysis. In a DOPPS report of 17,031 patients from 11 countries, higher dialysate bicarbonate concentrations were associated with an increased risk of all-cause mortality.58 Several mechanisms could explain these findings, none of which has been examined beyond small studies. Hypokalemia, reduction in ionized calcium, and prolongation of the QT interval due to rapid or excessive alkalinization could predispose to cardiac arrhythmia59–61; this would be linked specifically to cardiac arrest or sudden death during or in the hours immediately after a dialysis treatment. The DOPPS results appeared to be driven by an increase in infection-related mortality, which is not compatible with this hypothesis. High-bicarbonate dialysis may have a mild vasodilatory effect.62 In patients with intradialytic hypertension, this could be beneficial, but in others symptomatic hypotension may result.63,64 Over time, intradialytic hypotension may induce ischemic cardiac and cerebral injury, predisposing to cardiac arrhythmias, sudden death, and cognitive decline.65,66 That said, hemodialysis-induced left ventricular systolic dysfunction was not associated with change in pH or bicarbonate in a study of 105 patients receiving dialysis.67

Intradialytic hypoxemia could exacerbate ischemic injury and has been associated with mortality.68 Conceivably, hypoxemia could accompany the intradialytic hypercarbia noted above. Studies in patients with COPD have been inconclusive and data from patients with severe comorbidity are warranted.69–71 Finally, recurrent extracellular alkalinization could promote vascular calcification.72,73 This has never been thoroughly investigated in humans. The association with mortality in DOPPS was strongest among patients with longer dialysis vintage, and both vascular calcification and the sequelae of chronic ischemia would manifest after prolonged exposure to high-bicarbonate dialysate.

Although the DOPPS investigators found no difference in associations between the United States and other countries, it is important to recognize the drastic differences in practice patterns worldwide. The United States, which has higher ESRD-adjusted mortality rates than Europe or Japan,74,75 accounted for the majority of patients dialyzed with baths containing ≥38 mEq/L bicarbonate. In contrast, nearly 70% of German patients were dialyzed against bath bicarbonate ≤32 mEq/L. Japan is even more extreme (and was excluded from the recent DOPPS report); dialysate bicarbonate ≤30 mEq/L was prescribed for 83% of patients. To some extent, dialysate bicarbonate prescription could simply track with other country-level factors that associate with mortality.

The Anion in the Acid Concentrate

Bicarbonate was the buffer used when hemodialysis was first introduced.76 It was replaced by acetate due to the latter’s ease of use and the belief that the capacity for its metabolism far exceeded delivery.77 As technology progressed to enable modern proportioning systems and it became apparent that some patients experienced toxicity due to insufficient rates of acetate metabolism,78 bicarbonate again became the primary buffer. When admixed with an acid concentrate containing acetic acid, the final dialysate contains acetate concentrations too low to produce blood levels that clearly associate with toxicity.78 Modest elevations in blood acetate may be seen, but this can be observed even with bicarbonate dialysis absent an organic anion.79

The effect on acid-base balance is not clear. One would expect that the higher the acetate concentration in the dialysate, the more rapidly serum bicarbonate will rise. As a result, the dialysate–plasma bicarbonate gradient will decline more rapidly, so the net effect on serum bicarbonate should diminish with longer treatment time. Consequently, this likely affects early acid-base changes during a dialysis treatment but overall acid-base balance less so. Data from a subset of 7572 patients from the Japanese cohort support this hypothesis. Both pre- and postdialysis serum bicarbonate, as well as the intradialytic change, were lower among patients dialyzed against a 30 mEq/L bicarbonate bath versus 35 mEq/L, despite equal dialysate alkali content (6 mEq/L acetate and 1 mEq/L citrate were added to each, respectively).56 The dialysate bicarbonate is clearly the most important consideration.

Solutions are now available that use citric acid rather than acetic acid as the acidifying agent.80 These may improve dialysis efficiency, which has been attributed to reduced dialyzer clotting due to citrate’s anticoagulant effect. Greater buffer delivery and better correction of acidosis would be expected, but this has not been a consistent finding.81–85

Acid-Base Therapy in ESRD

Current guidelines mostly recommend maintaining serum bicarbonate ≥22 mEq/L in patients with CKD (the European Best Practice Guidelines suggest maintaining midweek predialysis serum bicarbonate at 20–22 mEq/L) on the basis of observational studies and small interventional studies.35,86–89 Thus the available evidence base provides only general guidance for clinicians, leaving room for substantial variability in clinical practice. For example, in some dialysis units the dialysis bicarbonate prescription is individualized, whereas in others a uniform prescription is used for all or nearly all patients.58 There are no trial data to support one practice over the other.

Several lines of evidence point to benefit from full correction of metabolic acidosis. In the two randomized trials of patients receiving peritoneal dialysis discussed earlier, the mean serum bicarbonate in the intervention groups reached levels that have been associated with increased mortality in patients receiving hemodialysis, yet they experienced improved outcomes.26,27 In the study that supplemented high lactate dialysate with oral alkali, the mean pH and serum bicarbonate at 1 year were 7.44 and 27.2 mEq/L, respectively, and this was the nadir bicarbonate level during the intervention.27 Mild alkalemia was associated with improved nitrogen balance in another study of patients receiving peritoneal dialysis, indicating decreased protein breakdown from full correction of acidosis.90 As associations of serum bicarbonate levels with mortality do not differ between peritoneal dialysis and hemodialysis patients, this suggests that high bicarbonate levels at the end of the interdialytic period are not harmful per se.39

However, observational studies do not associate high predialysis serum bicarbonate with improved outcomes, and we should be cautious about extrapolating data from patients receiving peritoneal dialysis to the hemodialysis population. The former provides a relatively continuous supply of buffer and a closer approximation of physiologic acid-base regulation than hemodialysis. Whereas the serum bicarbonate in a patient receiving peritoneal dialysis approximates steady-state, the predialysis serum bicarbonate in a patient receiving hemodialysis represents the peak of acid retention during the interdialytic period (Figure 2). The time-averaged serum bicarbonate during the interdialytic interval—which can be approximated by the difference between the postdialysis and predialysis bicarbonate level45—might provide a better comparison and treatment guide, although still not representative of a true steady-state.

Serum bicarbonate is not an optimal marker, despite associations with mortality, due to confounding by nutrition and other factors. Predialysis pH would better define a patient’s acid-base status, which could enable clinicians to tailor the prescription to an individual patient. Even a serum bicarbonate <20 mEq/L may be an unreliable predictor of acidemia,46 further underscoring the utility of measuring pH to guide management. Although associations of pH with mortality may be confounded by differences in respiratory status due to comorbidity, pH would still provide useful information for prescribing bicarbonate dialysis. Ideally, predialysis pH should be checked before changing the dialysate bicarbonate concentration or prescribing oral alkali, especially in patients with comorbidities such as congestive heart failure, chronic obstructive pulmonary disease, and cirrhosis.

The current evidence base does not sufficiently define the risks and benefits of aggressively treating metabolic acidosis with high-bicarbonate dialysate or oral alkali. Evaluation of a patient with predialysis serum bicarbonate outside the desired range should therefore focus on modifiable factors that accompany high or low bicarbonate levels in patients receiving dialysis. For high serum bicarbonate, this includes an assessment of nutritional status and a search for sources of inflammation. If the level is persistently high (>28 mEq/L), it seems reasonable to lower the dialysate bicarbonate to 30–32 mEq/L with close monitoring of subsequent serum bicarbonate levels. The evaluation of patients with low bicarbonate levels should focus on ensuring adequate dialysis and limiting interdialytic weight gain. Substituting plant protein for animal protein may be helpful,91 and in select patients, increasing fruit and vegetable intake. For patients with persistently low levels (<19 mEq/L) despite these interventions, base delivery can be increased either by raising the dialysate bicarbonate prescription or by administering oral alkali. The latter has often been frowned upon because of concerns about sodium loading and compounding dialysis patients’ already excessive pill burden.92 Therefore, changing dialysate bicarbonate is the most expeditious maneuver.

Even a modest number of pills, however, might increase serum bicarbonate to a level that a clinician considers acceptable. Four 650 mg tablets of sodium bicarbonate on nondialysis days would completely neutralize the average daily acid production of 28 mEq/d measured by Uribarri et al.53 Even half that amount could have a meaningful effect on acid-base status. Although the data from this small study may not be representative of the wider hemodialysis population, they suggest that net acid production for many patients is lower than what others have estimated.31 Of course, the patients who require such an intervention—those with a persistently low serum bicarbonate despite adequate dialysis—are likely to have above-average acid-generation rates (Figure 3), but a trial of oral sodium bicarbonate could be attempted and then discontinued if ineffective. Such an intervention, if tested, could permit lowering the dialysate bicarbonate and might help avoid both interdialytic acidosis and postdialysis alkalosis.

Figure 3.
Figure 3.

Daily acid-generation rate correlates inversely with predialysis serum bicarbonate level in patients receiving hemodialysis. All patients with daily acid-generation rates above the mean (28 mEq/L) had predialysis serum bicarbonate <24 mEq/L. Data from Uribarri et al. (n=15).53

In clinical practice, it is not entirely clear when to intervene, as variability within an individual patient may hamper clinical decision-making. We noted substantial month-to-month variability in a local cohort of patients receiving hemodialysis.37 A single abnormal serum bicarbonate (outside a normal range of 22–26 mEq/L for the purposes of this study) was as likely to return to normal the following month as to remain high or low. A low 3-month predialysis mean was more reproducible, but a high 3-month mean was twice as likely to be followed by a normal mean serum bicarbonate during the following 3 months as to remain high. Viewing results in the context of a patient’s prior variability may provide additional guidance, but this requires further study. This confounds not only the decision to begin an intervention, but also how to determine its effectiveness, and further suggests clinicians should be reticent about treating high predialysis serum bicarbonate values per se.

Some variability could be due to measurement error. Several reports identified spuriously low bicarbonate levels in samples drawn at dialysis units and shipped to central laboratories for measurement.93,94 This discrepancy was attributed to differences in assays, delays in sample processing, and loss of CO2 from the sample during shipment.93–95 However, the main culprit may have been the time samples were left uncapped in large commercial laboratories, which reduces the measured bicarbonate approximately 2.5 mEq/L per hour of exposure.96 Practices in the dialysis unit also matter. Partially-filled vacutainer tubes and samples left unspun for prolonged periods both spuriously lower the reported value; significantly underfilled tubes cause clinically meaningful reductions.97–99

Finally, a recent paper proposed a novel solution for minimizing intradialytic alkalosis while still adequately treating acidosis.100 The underlying premise is that expansion of the plasma bicarbonate pool in the early part of a dialysis treatment generates a gradient that is sufficient to replete intracellular buffers. Further alkali delivery causes alkalosis but does not have an important effect on buffer stores. Hence, high dialysate bicarbonate is useful initially but then detrimental, and the dialysate bicarbonate should be progressively lowered throughout the remainder of the dialysis treatment. Further work is needed to determine the utility of this maneuver as well as the specific dialysate modeling approach, but this is an intriguing proposal.

Conclusions

The optimal approach to managing acid-base balance is less well defined for patients receiving hemodialysis than for peritoneal dialysis. Adequately powered studies should test whether dialysis-induced alkalemia causes harm and whether benefit accrues from full correction of acidosis. The utility of using pH and the interdialytic averaged serum bicarbonate (postdialysis bicarbonate − predialysis bicarbonate)45 to guide treatment should also be examined. Optimal treatment may require knowledge of both pre- and postdialysis acid-base parameters, with individualized treatment decisions that weigh the risks of predialysis acidosis, rapid intradialytic alkalinization, and postdialysis alkalosis while accounting for a patient’s comorbidities. Further research would be needed to determine if the time and resources required of such an approach led to improved patient outcomes.

Disclosures

M.K.A. has consulted for Tricida, Inc., South San Francisco, CA.

Acknowledgments

This work was supported by K23 DK099438 from the National Institutes of Health (NIH). Its contents are solely the responsibility of the author and do not necessarily represent the official views of the NIH.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

References

  1. ↵
    1. Lyon DM,
    2. Dunlop DM,
    3. Stewart CP
    : The alkaline treatment of chronic nephritis. Lancet 218: 1009–1013, 1931
    OpenUrlCrossRef
  2. ↵
    1. Weller JM,
    2. Swan RC,
    3. Merrill JP
    : Changes in acid-base balance of uremic patients during hemodialysis. J Clin Invest 32: 729–735, 1953pmid:13069621
    OpenUrlPubMed
    1. Kolff WJ
    : Artificial kidney; treatment of acute and chronic uremia. Cleve Clin Q 17: 216–228, 1950pmid:14778188
    OpenUrlPubMed
  4. ↵
    1. Sanchezsicilia L,
    2. Kolff WJ
    : Acid-base equilibrium in patients with chronic renal failure in whom life is sustained by periodic hemodialyses. Report of five representative cases. Cleve Clin Q 31: 127–139, 1964pmid:14141713
    OpenUrlPubMed
  5. ↵
    Safety Alerts for Human Medical Products - Dialysate Concentrates Used in Hemodialysis: Safety communication - alkali dosing errors. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305630.htm. Accessed November14, 2012
  6. ↵
    Dialysis Company’s Failure to Warn of Product Risk Draws Inquiry: Available at http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html. Accessed November14, 2012
  7. ↵
    1. Gennari FJ
    : Acid-base balance in dialysis patients. Semin Dial 13: 235–239, 2000pmid:10923351
    OpenUrlPubMed
  8. ↵
    1. Uribarri J,
    2. Buquing J,
    3. Oh MS
    : Acid-base balance in chronic peritoneal dialysis patients. Kidney Int 47: 269–273, 1995pmid:7731157
    OpenUrlPubMed
  9. ↵
    1. Ballmer PE,
    2. McNurlan MA,
    3. Hulter HN,
    4. Anderson SE,
    5. Garlick PJ,
    6. Krapf R
    : Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95: 39–45, 1995pmid:7814640
    OpenUrlCrossRefPubMed
    1. DeFronzo RA,
    2. Beckles AD
    : Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236: E328–E334, 1979pmid:434194
    OpenUrlPubMed
    1. Reaich D,
    2. Channon SM,
    3. Scrimgeour CM,
    4. Goodship TH
    : Ammonium chloride-induced acidosis increases protein breakdown and amino acid oxidation in humans. Am J Physiol 263: E735–E739, 1992pmid:1415693
    OpenUrlPubMed
  12. ↵
    1. Mehrotra R,
    2. Kopple JD,
    3. Wolfson M
    : Metabolic acidosis in maintenance dialysis patients: Clinical considerations. Kidney Int Suppl 88: S13–S25, 2003pmid:14870874
    OpenUrlPubMed
  13. ↵
    1. Graham KA,
    2. Reaich D,
    3. Channon SM,
    4. Downie S,
    5. Gilmour E,
    6. Passlick-Deetjen J,
    7. Goodship TH
    : Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 49: 1396–1400, 1996pmid:8731105
    OpenUrlCrossRefPubMed
    1. Graham KA,
    2. Reaich D,
    3. Channon SM,
    4. Downie S,
    5. Goodship TH
    : Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 8: 632–637, 1997pmid:10495793
    OpenUrlAbstract
    1. Mak RH
    : Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 54: 603–607, 1998pmid:9690228
    OpenUrlCrossRefPubMed
    1. Pickering WP,
    2. Price SR,
    3. Bircher G,
    4. Marinovic AC,
    5. Mitch WE,
    6. Walls J
    : Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 61: 1286–1292, 2002pmid:11918735
    OpenUrlCrossRefPubMed
  17. ↵
    1. Reaich D,
    2. Graham KA,
    3. Channon SM,
    4. Hetherington C,
    5. Scrimgeour CM,
    6. Wilkinson R,
    7. Goodship TH
    : Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am J Physiol 268: E121–E126, 1995pmid:7840169
    OpenUrlPubMed
  18. ↵
    1. Graham KA,
    2. Hoenich NA,
    3. Tarbit M,
    4. Ward MK,
    5. Goodship TH
    : Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 8: 627–631, 1997pmid:10495792
    OpenUrlAbstract
  19. ↵
    1. Lefebvre A,
    2. de Vernejoul MC,
    3. Gueris J,
    4. Goldfarb B,
    5. Graulet AM,
    6. Morieux C
    : Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36: 1112–1118, 1989pmid:2557481
    OpenUrlCrossRefPubMed
  20. ↵
    1. Bossola M,
    2. Giungi S,
    3. Tazza L,
    4. Luciani G
    : Long-term oral sodium bicarbonate supplementation does not improve serum albumin levels in hemodialysis patients. Nephron Clin Pract 106: c51–c56, 2007pmid:17409769
    OpenUrlCrossRefPubMed
    1. Brady JP,
    2. Hasbargen JA
    : Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 31: 35–40, 1998pmid:9428449
    OpenUrlCrossRefPubMed
    1. Löfberg E,
    2. Gutierrez A,
    3. Anderstam B,
    4. Wernerman J,
    5. Bergström J,
    6. Price SR,
    7. Mitch WE,
    8. Alvestrand A
    : Effect of bicarbonate on muscle protein in patients receiving hemodialysis. Am J Kidney Dis 48: 419–429, 2006pmid:16931215
    OpenUrlCrossRefPubMed
    1. Movilli E,
    2. Viola BF,
    3. Camerini C,
    4. Mazzola G,
    5. Cancarini GC
    : Correction of metabolic acidosis on serum albumin and protein catabolism in hemodialysis patients. J Ren Nutr 19: 172–177, 2009pmid:19218045
    OpenUrlCrossRefPubMed
  24. ↵
    1. Oettinger CW,
    2. Oliver JC
    : Normalization of uremic acidosis in hemodialysis patients with a high bicarbonate dialysate. J Am Soc Nephrol 3: 1804–1807, 1993pmid:8329675
    OpenUrlAbstract
  25. ↵
    1. Williams AJ,
    2. Dittmer ID,
    3. McArley A,
    4. Clarke J
    : High bicarbonate dialysate in haemodialysis patients: Effects on acidosis and nutritional status. Nephrol Dial Transplant 12: 2633–2637, 1997pmid:9430864
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Szeto CC,
    2. Wong TY,
    3. Chow KM,
    4. Leung CB,
    5. Li PK
    : Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: A randomized placebo-control trial. J Am Soc Nephrol 14: 2119–2126, 2003pmid:12874466
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Stein A,
    2. Moorhouse J,
    3. Iles-Smith H,
    4. Baker F,
    5. Johnstone J,
    6. James G,
    7. Troughton J,
    8. Bircher G,
    9. Walls J
    : Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 52: 1089–1095, 1997pmid:9328950
    OpenUrlCrossRefPubMed
  28. ↵
    1. Lowrie EG,
    2. Lew NL
    : Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458–482, 1990pmid:2333868
    OpenUrlCrossRefPubMed
  29. ↵
    1. Bommer J,
    2. Locatelli F,
    3. Satayathum S,
    4. Keen ML,
    5. Goodkin DA,
    6. Saito A,
    7. Akiba T,
    8. Port FK,
    9. Young EW
    : Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 661–671, 2004pmid:15384017
    OpenUrlCrossRefPubMed
  30. ↵
    1. Wu DY,
    2. Shinaberger CS,
    3. Regidor DL,
    4. McAllister CJ,
    5. Kopple JD,
    6. Kalantar-Zadeh K
    : Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol 1: 70–78, 2006pmid:17699193
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Gotch FA,
    2. Sargent JA,
    3. Keen ML
    : Hydrogen ion balance in dialysis therapy. Artif Organs 6: 388–395, 1982pmid:7165553
    OpenUrlPubMed
    1. Rault R,
    : Optimal dialysate bicarbonate during hemodialysis. ASAIO transactions 37: M372–373, 1991
    OpenUrlPubMed
  33. ↵
    1. Vinay P,
    2. Prud’Homme M,
    3. Vinet B,
    4. Cournoyer G,
    5. Degoulet P,
    6. Leville M,
    7. Gougoux A,
    8. St-Louis G,
    9. Lapierre L,
    10. Piette Y
    : Acetate metabolism and bicarbonate generation during hemodialysis: 10 years of observation. Kidney Int 31: 1194–1204, 1987pmid:3110482
    OpenUrlPubMed
  34. ↵
    1. Gennari FJ
    : Acid-base homeostasis in end-stage renal disease. Semin Dial 9: 404–411, 1996
    OpenUrl
  35. ↵
    1. National Kidney Foundation
    : K/DOQI Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 35[Suppl 2]: S1–S140, 2000pmid:10895784
    OpenUrlPubMed
  36. ↵
    1. Amodu A,
    2. Abramowitz MK
    : Dietary acid, age, and serum bicarbonate levels among adults in the United States. Clin J Am Soc Nephrol 8: 2034–2042, 2013pmid:24052219
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Patel R,
    2. Paredes W,
    3. Hall CB,
    4. Nader MA,
    5. Sapkota D,
    6. Folkert VW,
    7. Abramowitz MK
    : Variability in monthly serum bicarbonate measures in hemodialysis patients: A cohort study. BMC Nephrol 16: 214, 2015pmid:26689440
    OpenUrlPubMed
  38. ↵
    1. Uribarri J,
    2. Levin NW,
    3. Delmez J,
    4. Depner TA,
    5. Ornt D,
    6. Owen W,
    7. Yan G
    : Association of acidosis and nutritional parameters in hemodialysis patients. Am J Kidney Dis 34: 493–499, 1999pmid:10469860
    OpenUrlPubMed
  39. ↵
    1. Vashistha T,
    2. Kalantar-Zadeh K,
    3. Molnar MZ,
    4. Torlén K,
    5. Mehrotra R
    : Dialysis modality and correction of uremic metabolic acidosis: Relationship with all-cause and cause-specific mortality. Clin J Am Soc Nephrol 8: 254–264, 2013pmid:23184567
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Kuriyama S
    : Characteristics of the clinical practice patterns of hemodialysis in Japan in consideration of DOPPS and the NKF/DOQI guidelines. Clin Exp Nephrol 12: 165–170, 2008pmid:18185907
    OpenUrlPubMed
  41. ↵
    1. Robinson BM,
    2. Akizawa T,
    3. Jager KJ,
    4. Kerr PG,
    5. Saran R,
    6. Pisoni RL
    : Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: Differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet 388: 294–306, 2016pmid:27226132
    OpenUrlPubMed
  42. ↵
    1. Agroyannis B,
    2. Fourtounas C,
    3. Tzanatos H,
    4. Dalamangas A,
    5. Vlahakos DV
    : Relationship between interdialytic weight gain and acid-base status in hemodialysis by bicarbonate. Artif Organs 26: 385–387, 2002pmid:11952511
    OpenUrlPubMed
    1. Tzanatos H,
    2. Dalamangas A,
    3. Retsa K,
    4. Kapetanaki A,
    5. Agroyannis B
    : Relation of interdialytic water retention with apparent bicarbonate space, HCO3-, and pH in hemodialyzed uremic patients. Ren Fail 27: 235–238, 2005pmid:15807191
    OpenUrlPubMed
  44. ↵
    1. Mioni R,
    2. Gropuzzo M,
    3. Messa M,
    4. Boscutti G,
    5. D’angelo A,
    6. Cruciatti A,
    7. Mioni G
    : Acid production and base balance in patients on chronic haemodialysis. Clin Sci (Lond) 101: 329–337, 2001pmid:11566068
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Graham KA,
    2. Hoenich NA,
    3. Goodship TH
    : Pre and interdialytic acid-base balance in hemodialysis patients. Int J Artif Organs 24: 192–196, 2001pmid:11394698
    OpenUrlPubMed
  46. ↵
    1. Marano M,
    2. Marano S,
    3. Gennari FJ
    : Beyond bicarbonate: Complete acid-base assessment in patients receiving intermittent hemodialysis [published online ahead of print March 21, 2016]. Nephrol Dial Transplant https://dx.doi.org/10.1093/ndt/gfw022doi: 10.1093/ndt/gfw022
  47. ↵
    1. Fan S,
    2. Ross C,
    3. Mitra S,
    4. Kalra P,
    5. Heaton J,
    6. Hunter J,
    7. Plone M,
    8. Pritchard N
    : A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 24: 3794–3799, 2009pmid:19666658
    OpenUrlAbstract/FREE Full Text
    1. Filiopoulos V,
    2. Koutis I,
    3. Trompouki S,
    4. Hadjiyannakos D,
    5. Lazarou D,
    6. Vlassopoulos D
    : Lanthanum carbonate versus sevelamer hydrochloride: Improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Ther Apher Dial 15: 20–27, 2011pmid:21272248
    OpenUrlPubMed
    1. Goldberg DI,
    2. Dillon MA,
    3. Slatopolsky EA,
    4. Garrett B,
    5. Gray JR,
    6. Marbury T,
    7. Weinberg M,
    8. Wombolt D,
    9. Burke SK
    : Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13: 2303–2310, 1998pmid:9761513
    OpenUrlAbstract/FREE Full Text
    1. Qunibi WY,
    2. Hootkins RE,
    3. McDowell LL,
    4. Meyer MS,
    5. Simon M,
    6. Garza RO,
    7. Pelham RW,
    8. Cleveland MV,
    9. Muenz LR,
    10. He DY,
    11. Nolan CR
    : Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65: 1914–1926, 2004pmid:15086935
    OpenUrlCrossRefPubMed
  51. ↵
    1. Ketteler M,
    2. Rix M,
    3. Fan S,
    4. Pritchard N,
    5. Oestergaard O,
    6. Chasan-Taber S,
    7. Heaton J,
    8. Duggal A,
    9. Kalra PA
    : Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3: 1125–1130, 2008pmid:18450923
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Noh US,
    2. Yi JH,
    3. Han SW,
    4. Kim HJ
    : Varying dialysate bicarbonate concentrations in maintenance hemodialysis patients affect post-dialysis alkalosis but not pre-dialysis acidosis. Electrolyte Blood Press 5: 95–101, 2007pmid:24459507
    OpenUrlPubMed
  53. ↵
    1. Uribarri J,
    2. Zia M,
    3. Mahmood J,
    4. Marcus RA,
    5. Oh MS
    : Acid production in chronic hemodialysis patients. J Am Soc Nephrol 9: 114–120, 1998pmid:9440095
    OpenUrlAbstract
  54. ↵
    1. Sepandj F,
    2. Jindal K,
    3. Kiberd B,
    4. Hirsch D
    : Metabolic acidosis in hemodialysis patients: A study of prevalence and factors affecting intradialytic bicarbonate gain. Artif Organs 20: 976–980, 1996pmid:8864017
    OpenUrlPubMed
  55. ↵
    1. Lim VS,
    2. Bier DM,
    3. Flanigan MJ,
    4. Sum-Ping ST
    : The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest 91: 2429–2436, 1993pmid:8514855
    OpenUrlCrossRefPubMed
  56. ↵
    1. Yamamoto T,
    2. Shoji S,
    3. Yamakawa T,
    4. Wada A,
    5. Suzuki K,
    6. Iseki K,
    7. Tsubakihara Y
    : Predialysis and postdialysis pH and bicarbonate and risk of all-cause and cardiovascular mortality in long-term hemodialysis patients. Am J Kidney Dis 66: 469–478, 2015pmid:26015276
    OpenUrlCrossRefPubMed
  57. ↵
    1. Symreng T,
    2. Flanigan MJ,
    3. Lim VS
    : Ventilatory and metabolic changes during high efficiency hemodialysis. Kidney Int 41: 1064–1069, 1992pmid:1513087
    OpenUrlCrossRefPubMed
  58. ↵
    1. Tentori F,
    2. Karaboyas A,
    3. Robinson BM,
    4. Morgenstern H,
    5. Zhang J,
    6. Sen A,
    7. Ikizler TA,
    8. Rayner H,
    9. Fissell RB,
    10. Vanholder R,
    11. Tomo T,
    12. Port FK
    : Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 62: 738–746, 2013pmid:23707043
    OpenUrlCrossRefPubMed
  59. ↵
    1. Di Iorio B,
    2. Torraca S,
    3. Piscopo C,
    4. Sirico ML,
    5. Di Micco L,
    6. Pota A,
    7. Tartaglia D,
    8. Berardino L,
    9. Morrone LF,
    10. Russo D
    : Dialysate bath and QTc interval in patients on chronic maintenance hemodialysis: Pilot study of single dialysis effects. J Nephrol 25: 653–660, 2012pmid:21983985
    OpenUrlCrossRefPubMed
    1. Heguilén RM,
    2. Sciurano C,
    3. Bellusci AD,
    4. Fried P,
    5. Mittelman G,
    6. Rosa Diez G,
    7. Bernasconi AR
    : The faster potassium-lowering effect of high dialysate bicarbonate concentrations in chronic haemodialysis patients. Nephrol Dial Transplant 20: 591–597, 2005pmid:15687112
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Gabutti L,
    2. Ross V,
    3. Duchini F,
    4. Mombelli G,
    5. Marone C
    : Does bicarbonate transfer have relevant hemodynamic consequences in standard hemodialysis? Blood Purif 23: 365–372, 2005pmid:16088104
    OpenUrlCrossRefPubMed
  62. ↵
    1. Gabutti L,
    2. Bianchi G,
    3. Soldini D,
    4. Marone C,
    5. Burnier M
    : Haemodynamic consequences of changing bicarbonate and calcium concentrations in haemodialysis fluids. Nephrol Dial Transplant 24: 973–981, 2009pmid:18842671
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Gabutti L,
    2. Ferrari N,
    3. Giudici G,
    4. Mombelli G,
    5. Marone C
    : Unexpected haemodynamic instability associated with standard bicarbonate haemodialysis. Nephrol Dial Transplant 18: 2369–2376, 2003pmid:14551368
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Graziani G,
    2. Casati S,
    3. Passerini P,
    4. Crepaldi M,
    5. Campise M,
    6. Ambroso G
    : Pathophysiology and clinical consequences of metabolic alkalosis in hemodialyzed patients. Arch Ital Urol Nefrol Androl 59: 105–111, 1987pmid:2976175
    OpenUrlPubMed
  65. ↵
    1. Eldehni MT,
    2. Odudu A,
    3. McIntyre CW
    : Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol 26: 957–965, 2015pmid:25234925
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Odudu A,
    2. Eldehni MT,
    3. McCann GP,
    4. McIntyre CW
    : Randomized controlled trial of individualized dialysate cooling for cardiac protection in hemodialysis patients. Clin J Am Soc Nephrol 10: 1408–1417, 2015pmid:25964310
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Assa S,
    2. Hummel YM,
    3. Voors AA,
    4. Kuipers J,
    5. Westerhuis R,
    6. de Jong PE,
    7. Franssen CF
    : Hemodialysis-induced regional left ventricular systolic dysfunction: Prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 7: 1615–1623, 2012pmid:22822014
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Meyring-Wösten A,
    2. Zhang H,
    3. Ye X,
    4. Fuertinger DH,
    5. Chan L,
    6. Kappel F,
    7. Artemyev M,
    8. Ginsberg N,
    9. Wang Y,
    10. Thijssen S,
    11. Kotanko P
    : Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis. Clin J Am Soc Nephrol 11: 616–625, 2016pmid:26936946
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Alfakir M,
    2. Moammar MQ,
    3. Ali MI,
    4. Alhatem E,
    5. Curran RD,
    6. Saoud RM,
    7. Chandran C,
    8. Khan MA,
    9. Debari VA
    : Pulmonary gas exchange during hemodialysis: A comparison of subjects with and without COPD on bicarbonate hemodialysis. Ann Clin Lab Sci 41: 315–320, 2011pmid:22166500
    OpenUrlAbstract/FREE Full Text
    1. Manca-Di-Villahermosa S,
    2. Tedesco M,
    3. Lonzi M,
    4. Della-Rovere FR,
    5. Innocenzi A,
    6. Colarieti G,
    7. Favarò A,
    8. Chamoun GM,
    9. Taccone-Gallucci M
    : Acid-base balance and oxygen tension during dialysis in uremic patients with chronic obstructive pulmonary disease. Artif Organs 32: 973–977, 2008pmid:19133027
    OpenUrlPubMed
  71. ↵
    1. Pitcher WD,
    2. Diamond SM,
    3. Henrich WL
    : Pulmonary gas exchange during dialysis in patients with obstructive lung disease. Chest 96: 1136–1141, 1989pmid:2805844
    OpenUrlCrossRefPubMed
  72. ↵
    1. Lomashvili K,
    2. Garg P,
    3. O’Neill WC
    : Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 69: 1464–1470, 2006pmid:16531981
    OpenUrlPubMed
  73. ↵
    1. Mendoza FJ,
    2. Lopez I,
    3. Montes de Oca A,
    4. Perez J,
    5. Rodriguez M,
    6. Aguilera-Tejero E
    : Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 73: 407–414, 2008pmid:17989650
    OpenUrlCrossRefPubMed
  74. ↵
    1. Goodkin DA,
    2. Bragg-Gresham JL,
    3. Koenig KG,
    4. Wolfe RA,
    5. Akiba T,
    6. Andreucci VE,
    7. Saito A,
    8. Rayner HC,
    9. Kurokawa K,
    10. Port FK,
    11. Held PJ,
    12. Young EW
    : Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14: 3270–3277, 2003pmid:14638926
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Foley RN,
    2. Hakim RM
    : Why is the mortality of dialysis patients in the United States much higher than the rest of the world? J Am Soc Nephrol 20: 1432–1435, 2009pmid:19443632
    OpenUrlFREE Full Text
  76. ↵
    1. Kolff WJ,
    2. Berk HTJ,
    3. Welle NM,
    4. van der Ley AJW,
    5. van Dijk EC,
    6. van Noordwijk J
    : The Artificial Kidney: A dialyser with a great area. J Am Soc Nephrol 8: 1959–1965, 1997pmid:9402100
    OpenUrlPubMed
  77. ↵
    1. Mion CM,
    2. Hegstrom RM,
    3. Boen ST,
    4. Scribner BH
    : Substitution of sodium acetate for sodium bicarbonate in the bath fluid for hemodialysis. Trans Am Soc Artif Intern Organs 10: 110–115, 1964pmid:5878395
    OpenUrlPubMed
  78. ↵
    1. Vinay P,
    2. Cardoso M,
    3. Tejedor A,
    4. Prud’homme M,
    5. Levelillee M,
    6. Vinet B,
    7. Courteau M,
    8. Gougoux A,
    9. Rengel M,
    10. Lapierre L,
    11. Piette Y
    : Acetate metabolism during hemodialysis: Metabolic considerations. Am J Nephrol 7: 337–354, 1987pmid:3324761
    OpenUrlCrossRefPubMed
  79. ↵
    1. Fournier G,
    2. Potier J,
    3. Thébaud HE,
    4. Majdalani G,
    5. Ton-That H,
    6. Man NK
    : Substitution of acetic acid for hydrochloric acid in the bicarbonate buffered dialysate. Artif Organs 22: 608–613, 1998pmid:9684700
    OpenUrlPubMed
  80. ↵
    1. Ahmad S,
    2. Callan R,
    3. Cole JJ,
    4. Blagg CR
    : Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 35: 493–499, 2000pmid:10692276
    OpenUrlPubMed
  81. ↵
    1. Kossmann RJ,
    2. Gonzales A,
    3. Callan R,
    4. Ahmad S
    : Increased efficiency of hemodialysis with citrate dialysate: A prospective controlled study. Clin J Am Soc Nephrol 4: 1459–1464, 2009pmid:19661218
    OpenUrlAbstract/FREE Full Text
    1. Gabutti L,
    2. Lucchini B,
    3. Marone C,
    4. Alberio L,
    5. Burnier M
    : Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: Consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol 10: 7, 2009pmid:19265544
    OpenUrlCrossRefPubMed
    1. Grundström G,
    2. Christensson A,
    3. Alquist M,
    4. Nilsson LG,
    5. Segelmark M
    : Replacement of acetate with citrate in dialysis fluid: A randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol 14: 216, 2013pmid:24103587
    OpenUrlCrossRefPubMed
    1. Kuragano T,
    2. Kida A,
    3. Furuta M,
    4. Yahiro M,
    5. Kitamura R,
    6. Otaki Y,
    7. Nonoguchi H,
    8. Matsumoto A,
    9. Nakanishi T
    : Effects of acetate-free citrate-containing dialysate on metabolic acidosis, anemia, and malnutrition in hemodialysis patients. Artif Organs 36: 282–290, 2012pmid:21954915
    OpenUrlPubMed
  85. ↵
    1. Molina Nuñez M,
    2. de Alarcón R,
    3. Roca S,
    4. Álvarez G,
    5. Ros MS,
    6. Jimeno C,
    7. Bucalo L,
    8. Villegas I,
    9. García MA
    : Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective cross-over study. Blood Purif 39: 181–187, 2015pmid:25791278
    OpenUrlCrossRefPubMed
  86. ↵
    1. National Kidney Foundation
    : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1–S201, 2003pmid:14520607
    OpenUrlPubMed
    1. Kidney Disease Improving Global Outcomes (KDIGO) CKD
    : KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013
    OpenUrlCrossRef
    1. Fouque D,
    2. Vennegoor M,
    3. ter Wee P,
    4. Wanner C,
    5. Basci A,
    6. Canaud B,
    7. Haage P,
    8. Konner K,
    9. Kooman J,
    10. Martin-Malo A,
    11. Pedrini L,
    12. Pizzarelli F,
    13. Tattersall J,
    14. Tordoir J,
    15. Vanholder R
    : EBPG guideline on nutrition. Nephrol Dial Transplant 22[Suppl 2]: ii45–ii87, 2007pmid:17507426
    OpenUrlFREE Full Text
  89. ↵
    1. Voss D,
    2. Hodson E,
    3. Crompton C
    : Nutrition and growth in kidney disease: CARI guidelines. Aust Fam Physician 36: 253–254, 2007pmid:17392940
    OpenUrlPubMed
  90. ↵
    1. Mehrotra R,
    2. Bross R,
    3. Wang H,
    4. Appell M,
    5. Tso L,
    6. Kopple JD
    : Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients. Am J Clin Nutr 90: 1532–1540, 2009pmid:19846545
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Scialla JJ,
    2. Anderson CA
    : Dietary acid load: A novel nutritional target in chronic kidney disease? Adv Chronic Kidney Dis 20: 141–149, 2013pmid:23439373
    OpenUrlCrossRefPubMed
  92. ↵
    1. Van Stone JC
    : Oral base replacement in patients on hemodialysis. Ann Intern Med 101: 199–201, 1984pmid:6430142
    OpenUrlCrossRefPubMed
  93. ↵
    1. Kirschbaum B
    : Spurious metabolic acidosis in hemodialysis patients. Am J Kidney Dis 35: 1068–1071, 2000pmid:10845818
    OpenUrlCrossRefPubMed
  94. ↵
    1. Bray SH,
    2. Tung RL,
    3. Jones ER
    : The magnitude of metabolic acidosis is dependent on differences in bicarbonate assays. Am J Kidney Dis 28: 700–703, 1996pmid:9158207
    OpenUrlCrossRefPubMed
  95. ↵
    1. Laski ME
    : Penny wise and bicarbonate foolish. Am J Kidney Dis 35: 1224–1225, 2000pmid:10845840
    OpenUrlCrossRefPubMed
  96. ↵
    1. Zazra JJ,
    2. Jani CM,
    3. Rosenblum S
    : Are the results of carbon dioxide analysis affected by shipping blood samples? Am J Kidney Dis 37: 1105–1106, 2001pmid:11325696
    OpenUrlPubMed
  97. ↵
    1. Berns SD,
    2. Matchett JL
    : Effect of phlebotomy technique on serum bicarbonate values. Acad Emerg Med 5: 40–44, 1998pmid:9444341
    OpenUrlPubMed
    1. Herr RD,
    2. Swanson T
    : Serum bicarbonate declines with sample size in vacutainer tubes. Am J Clin Pathol 97: 213–216, 1992pmid:1546690
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Howse ML,
    2. Leonard M,
    3. Venning M,
    4. Soloman L
    : The effect of different methods of storage on the results of serum total CO2 assays. Clin Sci (Lond) 100: 609–611, 2001pmid:11352775
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Tovbin D,
    2. Sherman RA
    : Correcting acidosis during hemodialysis: Current limitations and a potential solution. Semin Dial 29: 35–38, 2016pmid:26593391
    OpenUrlPubMed
View Abstract
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Request Permissions
Bicarbonate Balance and Prescription in ESRD
Matthew K. Abramowitz
JASN Mar 2017, 28 (3) 726-734; DOI: 10.1681/ASN.2016070780
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Recent Tweets about the Article

Keywords